Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.

Join us as we host Assembly Bio for an in-depth discussion on recurrent genital herpes (RGH). This talk will provide an overview of RGH epidemiology, real-world disease burden, and impact on affected individuals. We will review the current treatment landscape and patient journey, highlight the state of clinical science, and discuss the rationale for advancing long-acting therapeutic approaches.

The presentation will introduce Assembly Bio’s investigational candidates, ABI-5366 and ABI-1179, including their targets and differentiation relative to standard therapies such as valacyclovir. Finally, we will summarize Phase 1 findings and outline plans for Phase 2 development.

Speaker: Dr. Grace Wang, VP, Clinical Development, Assembly Bioscience
Moderator: Dr. Yoshi Murata, Executive Director, Virology Clinical Development, Gilead

Dr. Wang received her medical degree from Shanghai Medical University and practiced as an anesthesiologist before she joined industry. She has been working in the clinical development in pharmaceutical companies for more than 20 years. She has led drug research and development in neurosciences and infectious diseases. She joined Assembly Biosciences almost 5 years ago as a vice president in Clinical Development. She led the genital herpes clinical development programs at Assembly.

Register for this talk here: https://us06web.zoom.us/meeting/register/y3niff9HTaWUS6CgIvedig